We may soon have a third vaccine. Here’s what you need to know about the Johnson & Johnson shot
The results of a late-stage clinical trial for a new COVID-19 vaccine from Johnson & Johnson were hailed as good news, even though the company reported that its one-shot vaccine had a lower efficacy rate than its two-shot rivals — Moderna and Pfizer-BioNTech — which are already being administered to people across the US.
We asked and answered key questions about the new vaccine and how it compares to the others.
We have lots of e-mail newsletters on a variety of topics, including news, politics, business, sports, lifestyle, and more. They're free, and it's easy to subscribe. Here's a complete list.
You received this message because you signed up for Breaking News Alerts.
